NEW YORK (GenomeWeb) — OncoSec Medical, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it is working with the University of California, Los Angeles and PerkinElmer to develop molecular biomarkers to measure patients' immune responses to cancer.

OncoSeq said that the effort will use PerkinElmer’s imaging-based staining methods to quantitatively evaluate CD8+ T cell density, with the goal of developing markers that can distinguish responders from non-responders to anti-PD-1 monotherapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.